Biocad has plans to ship Remicade rival
Biocad has announced plans to begin shipping the firm’s biosimilar of Janssen’s Remicade (infliximab) to “global markets” towards the end of this year, or in early 2019.
You may also be interested in...
More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.